IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

American Journal of Pathology

Volumn 174, Issue 4, 2009, Pages 1149-1153

  Watanabe, Takuya ^a   Nobusawa, Sumihito ^a   Kleihues, Paul ^b   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; HISTONE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; PROTEIN P53; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; CANCER GROWTH; CARCINOGENESIS; CELL POPULATION; CELL SUBPOPULATION; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GLIA CELL; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PRIMARY GLIOBLASTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SECONDARY GLIOBLASTOMA; STEM CELL; TISSUE SECTION; AGE; BRAIN TUMOR; GENETICS; MIDDLE AGED; MUTATION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGE FACTORS; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65349150503     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080958     Document Type: Article

References (19)

1. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489
2. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899
3. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453
4. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H: Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000, 80:65-72
5. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, Konishi N: Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 2005, 85:165-175
6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (Eds): WHO Classification of Tumours of the Central Nervous System. Lyon, IARC, (2007)
7. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321: 1807-1812
8. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H: Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997, 3:523-530
9. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schuler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lutolf U, Kleihues P, Ohgaki H: Population-based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligo- dendrogliomas. Acta Neuropathol 2004, 108:49-56
10. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H: Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neu- ropathol 2001, 103:267-275
11. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C - A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719
12. Reifenberger G, Louis DN: Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003, 62:111-126
13. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997, 56:1098-1104
14. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002, 161:313-319
15. Burkhard C, Di Patre PL, Schuler D, Yasargil MG, Lütolf U, Kleihues P, Ohgaki H: A population-based study on the incidence and survival of patients with pilocytic astrocytoma. J Neurosurg 2003, 98: 1170-1174
16. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG: Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuro- pathol Exp Neurol 2008, 67:878-887
17. Narahara K, Kimura S, Kikkawa K, Takahashi Y, Wakita Y, Kasai R, Nagai S, Nishibayashi Y, Kimoto H: Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet 1985, 71:37-40
18. Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 1999, 274:30527-30533
19. Devlin TM: (Ed). Textbook of biochemistry with clinical correlations. Wiley-Liss, Hoboken, N.J. (2006)